We studied long-term pulmonary function testing (PFT) in a retrospective cohort of 6-month survivors of allogeneic marrow transplant (BMT) between 1980 and 1997. Of 593 patients, 73, 71 and 65% had adequate data to assess for obstruction, restriction and diffusion impairments respectively. Over 5 years, mean declines in 1-s forced expiratory volume/forced vital capacity (FEV1/FVC), total lung capacity (TLC) and diffusion were 4, 7 and 17%, respectively. TLC and diffusion tended to subsequently increase. In all, 6, 12 and 35% of patients met criteria for obstruction, restriction and impaired diffusion, respectively. Obstruction was less common in recent transplants (5 vs 15%, P ¼ 0.004), while restriction and diffusion impairment rates remained stable. There was significantly greater mortality with obstruction (HR 2.0 (1.04-3.95)), and a nonstatistically significant higher mortality rate with restriction (HR 1.6 (0.95-2.75)), but not with impaired diffusion (HR ¼ 0.99 (0.65-1.50)). cGVHD (OR 16.7 (2.2-129.8)) and busulfan (OR 2.9 (1.01-8.24)) were associated with obstruction. Marrow from nonsibling or mismatched donors (OR 4.9 (2.2-10.7)) was associated with restriction. In summary, after BMT, decreased diffusion capacity is common and benign; obstruction has decreased in frequency, is rare without cGVHD, and is associated with mortality; nonsibling and mismatched donor are risk factors for restriction.
Pulmonary function testing (PFT) after BMT is useful for predicting survival, given that PFT abnormalities correlate with nonrelapse mortality, 4 and the diagnosis of BMT complications, where PFT abnormalities make up some of the diagnostic criteria. 3, 5 There are three main categories of PFT abnormalities. Obstructive defects occur when there is small airway closure or obstruction on expiration, leading to diminished forced expiratory volumes (1-s forced expiratory volume -FEV1), classically with a preserved forced vital capacity (FVC), resulting in a decrease in FEV1/FVC ratio. In the BMT population, the prototypical cause of obstruction is OB. Its occurrence has been linked to cGVHD. 6 Restriction is a pattern of decreased lung volumes (including the total lung capacity -TLC) with a preserved FEV1/FVC ratio. Idiopathic pneumonia syndrome, a diffuse noninfectious pneumonitis is a prototypical cause of restriction and may be due to thoracic irradiation, chemotherapy or other causes. Pulmonary edema, infectious pneumonitis and bronchiolitis obliterans organizing pneumonia (BOOP) may also cause restriction post-BMT. The final PFT derangement is one of diminished diffusion capacity for carbon monoxide (DCO). A low DCO often reflects thickening of the alveolo-capillary interface, as occurs in several of the causes of restrictive lung disease. Hemoglobin level is a major determinant of DCO. Without correction for anemia, low hemoglobin would undoubtedly be the most common cause of impaired diffusion after BMT.
In a systematic review of PFT after BMT, Marras et al 6 found that there was a tendency for all reported PFT parameters to deteriorate. The most commonly observed abnormality post-BMT was a decrease in DCO with partial recovery, observed in 83% of patients. Restriction was the next most common, seen in 35%, and also generally improved over time. A total of 23% of subjects developed obstruction, which tended to be persistent. Risk factors for the development of PFT abnormalities were also identified. All PFT abnormalities were most often associated with GVHD. A long list of other risk factors, each one generally identified by only a single study, was also reported. This review had several important limitations. First, sample sizes in the included studies were generally small, and larger studies generally provided only a single, early post-BMT assessment. Second, data regarding the number of patients at each follow-up, the magnitude of changes in specific PFT measurements and the fraction of patients developing specific derangements were often incompletely reported. Third, there was heterogeneity in BMT treatment protocols, definitions of PFT abnormalities, follow-up times and patient populations (allogeneic vs autologous transplant recipients were not always distinguished). Possible biases in selecting patients for follow-up PFT were generally not addressed and most studies reported on patients transplanted in the 1980s. Given the clinical importance of PFT after BMT and the limitations of the published data, we studied 593 BMT patients at one institution to assess: (1) long-term changes in the FEV1/FVC ratio, TLC and DCO after BMT; (2) differences in rates of development of PFT abnormalities over time; (3) associations between new PFT abnormalities and mortality after BMT; and (4) predictors of new obstruction and new restriction after BMT in recently transplanted patients. We also attempted to develop a simple model to allow distinction between patients at high vs low risk for the development of persistent obstruction.
Methods

Patients and study site
This retrospective cohort study included all patients who received their first allogeneic BMT at our institution from 1980 to 1997, and survived for at least 6 months. Since we wished to study long-term PFT abnormalities, we excluded two groups of patients. We excluded patients who survived for less than 6 months, given the absence of long-term data available from this group. We excluded patients transplanted after 1997, because it was decided that patients should have the opportunity to contribute at least 36 months of follow-up data and the investigation was initiated in 2000. The study setting was the Princess Margaret Hospital (PMH)/Ontario Cancer Institute, a 100-bed tertiary-care cancer hospital, part of the University Health Network in Toronto, Ontario, Canada. This study was reviewed and approved by the institutional ethics board for the Princess Margaret Hospital.
Patient monitoring and data collection
All patients were followed clinically at the PMH. PFT is part of the routine protocol and is performed pre-BMT, at 4 and 12 months post-BMT and annually thereafter. Clinical information was obtained from patient records and PFT results from original laboratory reports. PFT data for this investigation included FEV1, FVC, FEV1/FVC ratio, TLC and DCO. Measurements were recorded as absolute measured values and percent of predicted normal values. DCO was corrected for hemoglobin in all the cases. PFT was performed with standard laboratory equipment according to American Thoracic Society guidelines. Until 1990, spirometry was performed with a wet-spirometer (Med Science Electronics model 750) combined with an XY recorder (HewlettPackard) with a 1-s timer. After 1990, spirometry was performed with a Spiroflow spirometer (PK Morgan, Chatham, England). All lung volumes (using a body plethysmograph) and measures of DCO (single breath carbon monoxide diffusion capacity with helium dilution alveolar volume) were done with equipment from PK Morgan (Chatham, England). There were no important changes in instrumentation, predictive formulae and PFT laboratory protocols during the study period. Data were entered directly into an electronic database (Access 2000 R , Microsoft, Redmond, Washington, USA). After initial data collection, one of the authors (TKM) reviewed 10% of the primary sources without knowledge of the previous data abstracted.
End point definitions
Definitions for specific PFT abnormalities included significant decreases in the measured parameter from pre-to post-BMT. This is analogous to the guidelines of the International Society of Heart and Lung Transplantation, where a 20% drop in the measured FEV1 is used to define bronchiolitis obliterans syndrome after lung transplant. 7 Thresholds for abnormality were set high, to ensure we studied truly significant PFT abnormalities, sacrificing some sensitivity for improved specificity.
Idiopathic obstruction was diagnosed in the absence of obvious causes and presumed to represent OB, defined as a fractional decrease of 20% in the FEV1/FVC absolute measurement (eg decrease from 0.8 to 0.64). Restriction was defined as a proportional decrease in the measured TLC of at least 20% (eg decrease from 5 to 4.5 l). Impaired diffusion was defined as a proportional decrease in the measured DCO of at least 25% (eg decrease from 20 to 15 ml/min/mmHg CO). The more stringent criterion for the development of impaired DCO was chosen due to the lower precision and greater variability of this test. 8 
Statistical analysis
Analyses were performed using SAS R version 8.0. (SAS Institute, Cary, NC, USA) and Epi Info 2000 (Centers for Disease Control and Prevention, Atlanta, Georgia, USA). Bivariate analyses comprised Yate's-corrected w 2 and Fisher's exact tests (two-sided) for categoric variables and t-tests (two-tailed) or Mann-Whitney-U depending on the underlying distribution. To study PFT changes after BMT, mean PFT values were plotted against time. To search for differences in rates of development of PFT abnormalities between recent and early era patients, multiple logistic regression was used, with the outcome (eg new obstruction) as the dependent variable and transplant era as one of the independent (predictor) variables. Transplant era, recent (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) vs early (1980) (1981) (1982) (1983) (1984) (1985) (1986) , was defined to coincide with the introduction of routine prophylactic cyclosporine and pre-emptive ganciclovir use in our program.
To identify associations between new PFT abnormalities and mortality, Kaplan-Meier survival curves were compared with the log-rank test. The Cox proportional hazards models were used for multivariable analyses, controlling for relapse, age, sex, disease duration and donor relation. To identify predictors of new obstruction and new restriction after BMT in recently transplanted patients, multiple logistic regression was used. Multiple logistic models were constructed using characteristics relating to pre-BMT (age, sex, diagnosis), BMT (HLA matching, conditioning regimen) and post-BMT (GVHD) status. To avoid overfitting, in the context of the relatively small number of outcomes, we selected only variables we considered most important and fit a full model (no selection techniques were employed). 9 Busulfan and total body irradiation were strongly negatively correlated, so in analyses containing these variables, the more informative of the two (based on full modeling) was selected for the final model. Cyclophosphamide was used in over 95% of patients and was therefore not studied due to inadequate variability.
Recursive partitioning (RP) was used to distinguish patients on the basis of their risk for the development of OB. RP involves the sequential partitioning of the sample into progressively more homogeneous subsets with distinct probabilities of developing the outcome of interest. 10 First we assessed the statistical significance of all explanatory variables of interest (two-sided Yate's-corrected w 2 or Fisher's exact tests). Continuous variables were dichotomized according to the best apparent threshold by visual inspection of plots. Next, we divided the cohort into highand low-risk groups by removing all patients with the explanatory variable with the lowest P-value. We then studied the lower risk group similarly, assessing all remaining explanatory variables, and removing patients with the variable with the next lowest P-value. Partitioning of the lower risk group was to proceed until no more statistically significant variables remained at the P ¼ 0.05 level. The final result of the RP yielded two groups of patients, the high-risk patients (who had any of the statistically significant explanatory variables) and low risk patients (who had none of the statistically significant variables.
The c index was used to assess the performance of the logistic regression and RP models in the original data set. The c index is the proportion of patient pairs who are discordant for the outcome (all possible pairs where one patient developed OB and the other did not), who are correctly distinguished by the model (the predicted probability of OB in the affected patient was greater than the predicted probability of OB in the unaffected patient).
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Comparison between c index values was made according to the method of Hanley and McNeil. 12 
Results
Patients and follow-up
Between 1980 and 1997, 873 patients received BMT at the study center and 593 survived for at least 6 months. Regarding accuracy of data collection, the second review of 10% of patient records showed that 2% of predictive characteristics data had been entered incorrectly. No inconsistency in classification of patients according to FEV1/FVC was found. Of 6-month survivors, 65% (385/ 593) were still alive at their last recorded follow-up visits, a median of 76 months post-BMT. Cause of death was determined in 97% (201/208) of nonsurvivors, and was relapse in 50% (100/201), sepsis in 24% (48/201), GVHD in 7% (14/201) and other causes in 19% (39/201). Nonrelapserelated respiratory deaths occurred in 25% (52/201) of deaths or 9% of 6-month survivors post-BMT. For PFT follow-up analyses, 434 (73%) patients had adequate FEV1/FVC data, 419 (71%) patients had adequate TLC data and 384 (65%) patients had adequate DCO data. Adequate PFT data was defined as pre-BMT and at least one measurement between 6 and 36 months post-BMT. Baseline characteristics of patients stratified by the presence of adequate PFT data are presented in Table 1 .
We found three main differences between patients with and without adequate PFT follow-up, all secondary to the finding of greater follow-up in recently transplanted patients. The first difference, a higher proportion of recent era patients in the group with adequate PFT follow-up, occurred because: (1) local follow-up at PMH has become more common to help ensure adequacy; (2) PFT follow-up in general has become more complete due to a better understanding of its prognostic importance; and (3) overall longer survival in recently transplanted patients (data not shown). The second and third differences were that patients without adequate PFT follow-up tended to be younger (consistent with the increase in mean age of patients receiving BMT in recent years), and had more often received previous thoracic radiotherapy (due to higher rates of previous radiotherapy in the early cohort (28% compared with 12%, Po0.0001)). Higher rates of previous radiotherapy have been prescribed in early cohort patients with acute leukemia, with craniospinal irradiation (classified as thoracic for the purposes of this investigation), and lymphoma with mantle distribution radiotherapy.
Information on CMV status and smoking history was unavailable in greater than 10% of patients and so was not studied. Spirometry pre-BMT was similar in patients with and without adequate follow-up data (mean FEV1/FVC 0.82 and 0.80, respectively, P ¼ 0.60). TLC pre-BMT was statistically significantly higher in patients with adequate PFT follow-up (104 vs 99% of predicted, P ¼ 0.002), as was DCO (88 vs 84% of predicted, P ¼ 0.03). Differences of this magnitude would not be considered clinically significant at the individual patient level.
PFT measurements after BMT
Overall trends in PFT measurements are shown in Figure 1 . Figure 1a shows that FEV1/FVC changed little in the entire patient group during the follow-up period. Overall, the mean (S.D.) FEV/FVC% decreased from 82% (7%) to 80% (8%). Individual patients who did not develop obstruction had a mean (S.D.) decline in FEV1/FVC of 2% (5%). Individual patients who developed obstruction experienced a mean (S.D.) decrease of 30% (15%). Figure 1b shows a small decrease in mean (S.D.) TLC from 104% (13%) pre-BMT to 100% (14%) at 1 year, which recovered to 106% (14%) at 5 years. Individual patients who never developed new restriction experienced a mean (S.D.) decrease in TLC of 5% (10%). Individual patients who did develop new restriction had a mean (S.D.) decrease in TLC of 27% (13%). These patients also tended to have a recovery in TLC over time. Plotting TLC data for subgroups of our study sample showed that the apparent increase in TLC in the entire group over time was not secondary to the inclusion of patients who develop OB (and may have an increase in TLC) or to lower PFT follow-up in patients with an initially low TLC (data not shown). Figure 1c shows that there was generally a decrease in DCO after BMT that improved with time. Overall, the mean (S.D.) DCO changed from 88% (16%) pre-BMT to 74% (16%) at 1 year and 82% (11%) at 5 years. Individual patients who did not reach the threshold for a new impairment of diffusion capacity had a mean (S.D.) decline in DCO of 5% (9%). Individual patients who did develop a new DCO impairment, by definition, had a greater mean (S.D.) decrease in DCO À27% (11%). Plots of PFT results to 10 years showed no change in any of the above trends, but are not presented due to the small number of patients with data beyond 5 years.
Early vs recent eras
Rates of obstruction, restriction and impaired diffusion are presented in Table 2 . There was a significantly lower rate of obstruction in the recent era, while rates of restriction and diffusion impairment were not statistically significantly different between eras. Plots of mean PFT measurements over time, divided by era, did not reveal any important differences in the magnitude of changes between early and recent cohort patients (data not shown).
Given the observed difference in obstruction, we assessed for other differences between the early and recent eras that may have contributed to the difference in outcome (Table 3) . Of variables for which there were baseline differences, multiple logistic regression analysis identified only busulfan to be associated with obstruction. However, despite its status as a risk factor for obstruction, and its increased use between cohorts, there was a decrease in the occurrence of obstruction. Early cohort BMT also remained associated with obstruction, despite controlling for other variables. Studying the use of cyclosporine as a possible explanatory variable was confounded by era (used very rarely in the early cohort) and by indication (routine prophylactic use in recent cohort vs salvage therapy in early cohort).
PFT derangements and mortality
Survival analysis results are presented in Figure 2 . All multivariable analyses were controlled for relapse, age, sex, Pulmonary function after allogeneic BMT TK Marras et al duration from diagnosis to BMT and donor relation. There was a statistically significant association between the development of obstruction and mortality in the uncontrolled survival analysis (log-rank P ¼ 0.049, Figure 2a) , and the multivariable Cox model (hazard ratio 2.0 (1.04-3.95) P ¼ 0.04). The statistically significant association between restriction and mortality in uncontrolled survival analysis (log-rank P ¼ 0.04, Figure 2b ), became nonstatistically significant in the multivariable Cox model (HR ¼ 1.8 (0.95-2.75) P ¼ 0.06). There was no significant association between a new diffusion impairment and mortality in uncontrolled survival analysis (log-rank P ¼ 0.51, Figure 2c) or in the Cox multivariable model (hazard ratio 0.99 (0.65-1.50) P ¼ 0.96).
Predictors of new obstruction
In total, 367 patients were transplanted in the recent era, survived for at least 6 months, and had adequate follow-up spirometry. A total of 5% (17/367) of patients developed significant obstruction. Baseline patient characteristics for recent cohort patients and the results of bivariate analyses according to the development of obstruction are presented in Table 4 . Patients who developed obstruction had a somewhat lower percent of predicted TLC pre-BMT. Both busulfan conditioning and cGVHD were also more common in patients who developed obstruction. Logistic regression analysis was used to model the risk of obstruction in recently transplanted patients. A full model was fit, using pre-BMT FEV1/FVC and TLC, age, busulfan conditioning, acute myelogenous leukemia (AML) and cGVHD. cGVHD (OR 16.7 (2.2-129.8)) and busulfan (OR 2.9 (1.01-8.24)) were the only statistically significant risk factors. There was a nonstatistically significant association between AML and a lower risk of obstruction (OR 0.73 (0.2-2.3)). No other variables were either statistically significant or demonstrated important trends. The predictive ability of this model in the original dataset was characterized by a sensitivity of 82%, a specificity of 60% and a c index of 0.71 (0.51-0.91), indicating better than chance predictive ability.
RP identified cGVHD as the only significant risk factor. The final RP model had a sensitivity of 94%, a specificity of 52% and a c index of 0.73 (0.56-0.91), indicating a better than chance predictive ability. The difference between c index values of the logistic regression and RP models was not statistically significant (difference 0.02 (À0.28, 0.24)).
Predictors of new restriction
A total of 358 patients were transplanted in the recent era, survived for at least 6 months, and had adequate lung volume follow-up. In all, 12% (42/358) of patients developed restriction. Baseline patient characteristics for recent cohort patients and the results of bivariate analyses according to the development of restriction are presented in Table 4 . Donor relation and HLA matching were the only statistically significant factors. Patients receiving marrow from HLA-matched unrelated, HLA-matched nonsibling, or single-antigen-mismatched donors had higher rates of subsequent restriction than patients with grafts from other donor types. In the logistic regression, patients receiving marrow from HLA-matched unrelated, HLA-matched nonsibling or single-antigen-mismatched sibling donors were more likely to develop restriction (OR 4.9 (2.2-10.7)). However, neither logistic regression nor RP generated a predictive index that could be clinically useful to identify the majority of patients at high risk of restriction.
Discussion
We present the results of long-term PFT follow-up in a large cohort of patients after allogeneic BMT. Our definition of obstruction was developed to be consistent with a diagnosis of post-BMT OB, including new, unexplained and persistent obstruction. We observed that in the cohort as a whole, the FEV1/FVC remained quite stable, but a small proportion of patients developed a significant decrease. Visual inspection of Figure 1a reveals a marked difference in shape of the curves as well as measurement of FEV1/FVC magnitude between patients with and without new obstruction. This suggests that there are two distinct populations of patients, those with and without OB, supporting the concept of a PFT-defined syndrome. Regarding restriction, we believe that similarly there are two populations of post-BMT patients, those with and without restriction, a notion supported by the distinctly different curves in Figure 1b . However, there may not be a clear distinction between patient populations with and without new diffusion impairments, given the generally parallel curves between those with and without this PFT-defined end point. Our survival analyses support distinguishing between patients with and without obstruction (higher mortality) and probably restriction (point estimate suggests increased mortality) but not impaired diffusion.
Obstruction was associated with era of transplant, with a significantly lower risk in patients transplanted after 1986. Compared with a recent systematic review, the trend in overall FEV1/FVC is consistent, but the rate of new obstruction we observed (6% in the entire cohort) was far lower than the rate of 35% in the review. 6 This difference is likely due to our stringent definition of obstruction and the relatively recent date of transplant of most of our patients (we observed a far higher rate in the early cohort). The reason for the decrease in obstruction in the recent era is unclear. Overall rates of cGVHD were not different between eras, although we did not study the severity and extent of cGVHD. Cyclosporine use has been postulated to decrease the rates of OB, 13 but we were unable to adequately study this. Confounding by era (essentially all patients in the recent cohort received cyclosporine) prevented studying cyclosporine as an explanatory variable in the analysis restricted to recent era patients. Confounding by indication (in the early cohort, cyclosporine was used as salvage therapy, in very sick patients, often with obstruction already present) obscured any association between cyclosporine and protection from OB in analyses Table 3 Early vs recent cohort patient characteristics in patents assessed for obstruction of all patients. The possibility remains that the use of cyclosporine is largely responsible for the observed decrease in OB.
In recently transplanted patients, cGVHD and busulfan conditioning were significant risk factors for obstruction, consistent with previous reports. We also observed a significant association between obstruction and mortality, which has not, to our knowledge, previously been reported. This finding is plausible given the high mortality associated with OB 3 and because our definition of obstruction was developed as a diagnostic surrogate for OB. Given the limited success in reversing established disease and the high mortality of OB after BMT, early detection should be a priority. The finding that the absence of cGVHD essentially rules out the development of severe obstruction suggests that this criterion could be used to help target heightened PFT surveillance for early detection of OB. Early detection could be implemented through the use of hand-held spirometric devices issued to high-risk patients. In our recent cohort, approximately 50% of patients would have been identified by the presence of cGVHD, decreasing the resources required to implement such a program.
Lung volume measurements over time showed a pattern similar to that seen in obstruction. Average TLC in the entire cohort was relatively constant overall, while a subset of patients (12%) developed significant restriction. No change was detected in the rate of restriction between early and recent cohorts. These observations differ markedly from those of a recent review, where the average TLC decreased by 16% of predicted and subsequently nearly completely recovered. 6 The reported rate of restriction was also nearly three-fold higher, as 35% of patients across studies developed restriction. The large discrepancies could be explained by differences in the definition of restriction (we required a significant decrease in TLC from baseline, not generally used by studies in the systematic review), or by different selection of study subjects. It is difficult to determine differential effects of selection bias given the absence of data regarding patients without adequate PFT data in most previous studies. We did observe shorter survival in patients without adequate PFT follow-up, but this was generally relapse-related, which would not be expected to significantly alter the TLC. We could not detect other obvious sources of bias in our sampling process.
Only HLA match and donor relation were found to be significantly associated with the development of restriction, an association not reported in a review of previous studies. 6 To ensure that the development of obstruction, which is commonly associated with an increase in TLC, did not dilute an underlying decrease in TLC, the analyses were repeated in two ways. First, we excluded patients who developed obstruction in both bivariate and multivariable analyses and second we modeled an interaction term comprising obstruction and restriction in the multivariable analysis. In both methods, there was no significant effect on the observed associations. One explanation for the association between restriction and HLA match or donor relation could be as a result of GVH, which should increase with decreasing HLA match or donor relation. There was an association between HLA mismatch or decreasing donor relatedness with cGVHD, but there was no significant association between cGVHD and restriction. It may be that an immunologic graft vs lung process, which does not present with the other manifestations of cGVHD, causes restriction. We are unaware of any direct associations reported between idiopathic pneumonia syndrome, a possible cause of restriction after BMT, and HLA mismatch or decreasing donor relatedness, and were unable to study this in our data set.
We observed a higher rate of mortality in patients with restriction that was not statistically significant. An analogous but statistically significant observation was made by Crawford et al, 4 who reported a relative risk of mortality of 2.3 in patients with a decrease in their TLC of at least 15%. The consistency of the direction and magnitude of this association, despite differences in analytic methods and patient populations, suggests that restriction is likely an important prognostic factor.
Diffusion measurement showed a decrease in the immediate post-BMT period with a subsequent incomplete recovery. The magnitude of the decrease matched that found in the recent review almost precisely. 6 There was no association between a significant drop in DCO and mortality, consistent with the findings of Crawford et al. 4 Our study has several important limitations. First, incomplete PFT follow-up may have biased our results and we addressed this by studying characteristics of patients with and without PFT follow-up. The greater follow-up in the recent cohort would suggest that data from this group are less biased. Given that the majority of our observations are from recent cohort patients, limiting risk factor analyses to recent cohort patients should minimize bias without sacrificing much data and increase generalizability to contemporary patients. Second, we were unable to assess whether cyclosporine is associated with lower rates of obstruction due to confounding by era (minimal cyclosporine use in early cohort) and indication (cyclosporine use in early cohort generally limited to 'salvage' situations). Third, also limited by incomplete data, we could not study whether additional variables of interest, including cytomegalovirus or smoking, were risk factors for PFT impairments. This may have contributed to relatively poor predictive value of our multivariable models of obstruction and restriction after BMT. The latter limitation adds to the call made by others to improve routine data collection in BMT patients for use in future investigations. 14 In summary, in a large group of patients who received BMT, we observed that approximately 6% had a major decrease in the FEV1/FVC ratio consistent with the onset of OB. Patients with OB almost universally had predating cGVHD and had greater mortality. Restriction was seen in 12% of patients, was associated with HLA mismatch and decreasing donor relatedness, and a trend toward increased mortality. Impairments of diffusion occurred in 35%, which tended to improve and were not associated with mortality. 
